semaglutide and nonarteritic anterior ischemic optic neuropathy linked to increased risk of severe eye condition NAION in new study Last month, the European Medicines

& McArdle, H

However, the agencies analyses at the time were hindered by the small number of reported instances of suicidal thoughts and behaviors, resulting in what the FDA on Monday called considerable uncertainty in the risk estimate. For more clarity on the matter, the agency conducted a meta-analysis of different GLP-1 trials, encompassing more than 90 studies and nearly 108,000 patients

Acute injuries: Noticeable improvements within 1-2 weeks Chronic conditions: Gradual improvement over 3-6 months Degenerative diseases: Variable response, often requiring longer treatment durations Table: Condition-Specific Response Timelines Patch Material and Cell Type Influences The type of stem cell patch and cells used matters a lot

If you take a reduced dose, you run the risk of the drug disappearing from your system faster than intended, he said

BPC-157 and TB-500: Regenerative adjuncts that may support angiogenesis, tissue repair, and nitric oxide signaling

The approval positions the pill as a potential alternative to injectable GLP-1 therapies and is expected to become available in the US in early January 2026